Ibere Pharmaceuticals Gross Profit

The latest gross profit for IBER is $-1.7M as of September 2022. That is below the sector sector average of $760M. Investors often review this figure alongside Ibere Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, IBER currently prints $-1.7M for gross profit, while the sector average sits near $760M. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Ibere Pharmaceuticals's growth, margins, and balance sheet.

A gross profit figure of $-1.7M for IBER is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $760M. Explore the charts below for those layers of context.

After noting IBER's gross profit ($-1.7M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.